OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedBluecross IdahoPolicy MP 7.01.63

Deep Brain Stimulation

Customize your policy alerts

Sign up for Bluecross Idaho Policy MP 7.01.63 alerts

Get alerted when Policy MP 7.01.63 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical necessity and coverage of deep brain stimulation (DBS) procedures for movement and selected neurologic disorders for members covered by Blue Cross of Idaho benefit plans.

Policy Summary

PayerBluecross Idaho

PolicyDeep Brain Stimulation

Policy CodePolicy MP 7.01.63

Change TypeInvestigational indication addedliterature update

Effective Date04/30/2026

Last ReviewApr 30, 2026

Next Review Date04/30/2026

Key ActionObtain prior authorization and document diagnosis, prior therapies tried and failed, and device/target details when requesting DBS.

SourceLink

POLICY UPDATE CHANGES

Adaptive deep brain stimulation in Parkinson disease was added to the policy evidence review and investigational policy statement.

Policy updated with literature review through April 9, 2026 and references added; Blue Cross of Idaho adopted changes effective 04/30/2026.

Apr 9, 2026latest literature update

04/30/2026Effective date

5 yrsfollow-up duration reported

78.8%aDBS adverse events

82-91%tremor suppression (TEC)

Coverage Criteria and Evidence-based Indications

Medically Necessary Indications

Covered when ALL of the following are met:

Thalamic DBS for tremor (unilateral): Unilateral DBS of the thalamus is medically necessary for individuals with disabling, medically unresponsive tremor due to essential tremor or Parkinson disease.

Disabling, medically unresponsive tremor defined per Policy Guidelines (see documentation requirements).

Thalamic DBS for tremor (bilateral): Bilateral DBS of the thalamus is medically necessary for individuals with disabling, medically unresponsive tremor in both upper limbs due to essential tremor or Parkinson disease.

GPi or STN DBS for Parkinson disease: Unilateral or bilateral DBS of the globus pallidus interna (GPi) or subthalamic nucleus (STN) is medically necessary for individuals with Parkinson disease who have: (1) a good response to levodopa; AND (2) motor complications not controlled by pharmacologic therapy; AND (3) EITHER a minimum motor UPDRS score of 30 when off medication (~12 hours) OR Parkinson disease duration of at least 4 years.

Policy Summary

PayerBluecross Idaho

PolicyDeep Brain Stimulation

Policy CodePolicy MP 7.01.63

Change TypeInvestigational indication addedliterature update

Effective Date04/30/2026

Last ReviewApr 30, 2026

Next Review Date04/30/2026

Key ActionObtain prior authorization and document diagnosis, prior therapies tried and failed, and device/target details when requesting DBS.

SourceLink

On This Page

UPDRS motor >=30 off meds OR PD duration >=4 years

Levodopa responsiveness typically defined as >=50% motor improvement with dopaminergic medication in trials.

DBS for primary dystonia: Unilateral or bilateral DBS of GPi or STN is medically necessary for individuals older than 7 years with chronic, intractable (drug-refractory) primary dystonia (including generalized/segmental dystonia, hemidystonia, and cervical dystonia).Age > 7 years

Chronic, intractable defined by inadequate response to conservative therapies; RCT evidence supports short blinded benefit with maintained open-label improvements.

Investigational / Not Covered Indications

Investigational uses: Adaptive deep brain stimulation for Parkinson disease; DBS for other movement disorders (for example, tardive dyskinesia and post‑traumatic dyskinesia); DBS for chronic cluster headache; and DBS for other psychiatric or neurologic disorders (including but not limited to epilepsy, Tourette syndrome, depression, obsessive‑compulsive disorder, anorexia nervosa, alcohol addiction, Alzheimer disease, multiple sclerosis tremor, and chronic pain) are considered investigational and not covered.

See Policy Guidelines for aDBS labeling limitations and safety considerations.

Evaluated Indications

Covered populations and interventions evaluated in the evidence review

Population and Intervention: Individual has essential tremor or tremor in Parkinson disease OR has symptoms associated with Parkinson disease (e.g., rigidity, bradykinesia, motor fluctuations); AND the proposed intervention is deep brain stimulation targeting the thalamus, subthalamic nucleus (STN), or globus pallidus interna (GPi), performed unilaterally or bilaterally as clinically indicated.

Derived from PICO populations and interventions described in the review.

General evidence-based indications

Clinical evidence supports DBS when patients have levodopa-responsive Parkinson disease with significant motor complications despite medical therapy and meet trial-based eligibility features.

Trial-informed eligibility features: Patients with Parkinson disease who are levodopa-responsive and have disabling motor symptoms or motor complications not controlled by optimized medical therapy; trial cohorts typically included disease duration >=4 years, age ranges that in some trials were 18–60 years, and >=50% motor improvement with dopaminergic medication.

Eligibility features derived from Schuepbach et al RCT and systematic reviews; intent is to mirror trial selection criteria for candidate selection.

Evidence summaries (informing coverage)

Summary of trial-based findings informing coverage considerations

Adaptive DBS efficacy: The ADAPT‑PD randomized trial reported primary success rates of 78.9% for single‑threshold aDBS and 91.0% for dual‑threshold aDBS for increasing 'On' time without troublesome dyskinesia compared with continuous DBS baseline in the trial's full‑analysis sets.

Primary endpoint derived from patient‑reported Parkinson's Disease Home Diary; analysis sets and sensitivity analyses influenced confidence bounds.

Adaptive DBS safety: In ADAPT‑PD overall 78.8% of subjects experienced adverse events, 56.5% had device‑related events, and 17.6% experienced serious adverse events; serious device‑related injuries were reported in individual participants.

Safety findings based on the full cohort (n=85) with smaller efficacy FAS; safety profile important in coverage considerations.

Primary dystonia efficacy: RCTs (Kupsch 2006; Volkmann 2014) and systematic reviews reported significant short‑term improvements in dystonia severity with pallidal or subthalamic DBS versus sham, with open‑label extensions showing maintained benefit in many patients.

Blinded periods typically 3 months; outcomes measured by BFMDRS and TWSTRS in trials cited.

Primary dystonia safety: Adverse events in RCTs included dysarthria and other stimulation‑related effects; in Volkmann et al. 63% of neurostimulation patients had adverse events during the blinded period, including serious events and some persistent dysarthria.

Safety profiles and reversibility of some events noted in trials inform counseling and documentation requirements.

Primary Dystonia — Evidence

Evidence summary and applicability for coverage decisions

Evidence supports DBS for primary dystonia: Multiple RCTs (Kupsch 2006, Volkmann 2014, Wang 2025) demonstrated greater improvement in dystonia severity scores with active DBS versus sham during blinded periods, with maintained improvements in open‑label follow‑up for many patients.

Blinded periods were typically 3 months; outcomes included BFMDRS and TWSTRS; pediatric data suggest benefit in selected children older than 7 years.

Tardive Dystonia/Dyskinesia — Evidence

Tardive dystonia/dyskinesia evidence and limitations

Tardive dystonia evidence limited: One randomized controlled trial (Gruber et al. 2018) randomized 25 patients to pallidal DBS versus sham and did not find a statistically significant between‑group difference at 3 months; the study was underpowered (planned N=48) and adverse events occurred in 10/25 patients with 3 serious events.

Given the single small RCT and supporting case series, evidence is insufficient to establish net health benefit broadly.

Population and general eligibility

Covered when ALL of the following are met:

Eligibility for DBS in epilepsy: Patient has drug‑resistant epilepsy as defined by failure of adequate trials of antiseizure medications (at least 2 appropriately chosen and tolerated AEDs); AND patient is not a candidate for resective epilepsy surgery (for example, multifocal onset or generalized onset); AND documentation of baseline seizure frequency and prior therapies, including trials of appropriate non‑surgical options (pharmacologic, VNS, ketogenic diet when applicable).

Responder defined as ≥50% seizure reduction in trial literature; QOLIE‑31 minimally important change = 5 points.

Evidence considerations for tardive syndromes and epilepsy

Coverage decisions should consider evidence strength and study limitations:

Tardive dystonia/dyskinesia evidence: One underpowered RCT (Gruber et al. 2018) showed no significant benefit at 3 months versus sham, while case series report symptomatic reductions; the small randomized evidence and short blinded follow‑up limit confidence in efficacy estimates.

Adverse events and study power limitations should be considered when evaluating requests.

Epilepsy evidence: Meta‑analysis of thalamic DBS (49 studies, n=1,125) reported mean seizure reductions ~62% and responder rates ~61–69%, but most studies were nonrandomized and uncontrolled; the largest RCT (SANTE, N=110) had mixed blinded‑phase findings and serious device‑related adverse events (~35%), limiting certainty of net benefit.

Long‑term responder rates improved in selected cohorts but interpretation limited by attrition and uncontrolled follow‑up.

Evidence summary supporting coverage considerations

Summary of evidence and implications:

Key findings from randomized and observational studies: The SANTE trial (N=110) had a 3‑month blinded phase with mixed results (some reduction in seizures in month 3 but no difference in 50% responder rates during the blinded phase); uncontrolled long‑term follow‑up and observational studies reported substantial median seizure reductions versus baseline, but lack of concurrent controls and attrition limit interpretation.

Median change in seizure frequency improved over time in follow‑up cohorts; responder rates increased in completers at long‑term follow‑up.

Safety considerations: Device‑related serious adverse events occurred in roughly one‑third of patients in SANTE (for example, implant‑site infection ~10%, malpositioned leads ~8.2%); neuropsychiatric adverse events such as depression and memory impairment were reported.

Many serious adverse events occurred early post‑implant; documentation of anticipated risks should accompany authorization requests.

Evidence certainty: Overall evidence for thalamic DBS in epilepsy is heterogeneous, dominated by nonrandomized studies, with only limited randomized data showing inconsistent blinded‑phase benefits; the risk–benefit ratio is therefore uncertain and further trials are needed to establish net health benefit.

DBS has not been directly compared to VNS in randomized trials per the review.

Tourette syndrome selection and outcomes

Patient selection considerations for Tourette syndrome:

Population: Individuals with Tourette syndrome who have disabling tics refractory to optimal medical management and behavioral therapy (e.g., habit reversal), with documentation of tic severity and functional impairment.

Comorbid ADHD or OCD is common and should be documented and managed alongside tic treatment.

Intervention and targets: DBS targeting medial thalamus, subthalamic nucleus, globus pallidus interna (anteromedial or posteroventrolateral regions), caudate, or anterior limb of internal capsule/nucleus accumbens have been investigated; target selection should be justified in the record.

Multiple targets reported across studies; rationale for chosen target should be documented.

Outcomes to document: Baseline and serial follow‑up measures such as YGTSS, functional ability, medication use, and quality of life; safety outcomes to document include death, stroke, depression, cognition changes, infection, and device/procedure events.

These outcome measures mirror those used in the evidence base and inform assessment of benefit and harm.

Tourette syndrome — evidence and coverage implications

Evidence summary and implications for coverage decisions:

RCT evidence: Randomized crossover and sham‑controlled trials for Tourette syndrome have mixed results: Kefalopoulou et al. (2015) reported a modest but statistically significant YGTSS improvement in completers, while Welter et al. (2017) found no significant difference at 3 months; trials were small and heterogeneous.

Two RCTs with >=15 patients reported discordant results and high rates of serious adverse events.

Pooled/observational evidence: Systematic reviews and pooled analyses report substantial within‑subject reductions in YGTSS (median ~53–56% reduction) and high proportions achieving >=25% or >=50% improvement in uncontrolled series, but studies are heterogeneous and often small or single‑arm.

Registry data show meaningful group‑level improvements but with significant adverse event rates.

Safety and adverse events: High rates of serious adverse events reported across trials and registries including infections, intracranial hemorrhage, electrode misplacement, lead explantation, and neuropsychiatric events; these risks must be weighed against possible benefit.

International registry reported adverse event proportion and RCTs reported multiple serious events.

Coverage consideration: Because of mixed randomized evidence, heterogeneity of stimulation targets, and significant adverse events, coverage decisions for Tourette syndrome should require documentation that the patient has severe, medically refractory disease, failure of guideline‑recommended therapies, and treatment at experienced centers with a plan for follow‑up and outcome reporting.

Documentation expectations align with trial‑style selection principles.

Cluster headache and facial pain — clinical context

Clinical context and comparator treatments for cluster headache and facial pain:

Standard care before considering DBS: Guideline‑recommended acute therapies (oxygen inhalation, triptans) and prophylactic agents (verapamil, steroids), botulinum toxin for facial pain, and other conservative measures should be attempted prior to considering DBS; sham‑controlled trials are particularly relevant because of high placebo response in cluster headache.

Fontaine et al. RCT showed no difference between active and sham stimulation in randomized phase; systematic review/meta‑analysis evidence limited to small samples.

Evidence summaries for DBS indications

Evidence and clinical trial findings summarized for indication-specific consideration

Cluster headache/facial pain evidence summary: Systematic reviews and small controlled trials report short‑term reductions in pain intensity for some patients, but an 11‑patient randomized crossover trial found no significant difference between active and sham stimulation during the randomized phase; larger controlled trials are needed.

High placebo response in this condition reduces certainty of uncontrolled series.

Treatment‑resistant depression evidence summary: Systematic reviews and meta‑analyses across various DBS targets report modest pooled reductions in depression scales and variable response/remission rates (for example, ~57% response in subcallosal cingulate open‑label pooled analyses), but randomized sham‑controlled trials have had mixed or negative blinded‑phase results and psychiatric adverse events are a concern.

Targets and trial designs heterogeneous; several RCTs terminated for futility or failed to show blinded benefit.

Summary criteria — evidence and implications

Evidence summary and implications for coverage decisions

Efficacy for Major Depressive Disorder: Randomized trials and meta‑analyses for DBS in treatment‑resistant depression have not consistently shown benefit versus sham; some trials were terminated for futility and others reported no significant primary outcome differences in blinded phases, although open‑label follow‑up sometimes shows symptom improvements.

Absence of consistent blinded benefit limits coverage as established therapy outside research.

Safety concerns: Trials report psychiatric adverse events including worsening depression, hypomania, suicidal ideation, and device‑related complications; adverse events sometimes occurred more frequently in active arms.

Safety profile important when evaluating requests for investigational psychiatric indications.

OCD evidence: Randomized and pooled data for DBS in OCD suggest symptom reductions and higher odds of response with active DBS in some analyses, but studies are small, heterogeneous across targets, and rated low certainty—further blinded trials are needed to define net health benefit and optimal targets.

IPD meta‑analysis reported OR for response but overall evidence graded low certainty.

Condition-specific evidence summaries

Evidence summaries and coverage-relevant conclusions for specific conditions in this document portion:

Obsessive‑Compulsive Disorder (OCD): RCTs and meta‑analyses report symptom improvement after DBS (mean ~47% decrease in Y‑BOCS; pooled responder ~66% in some analyses), but studies are small, at risk of bias, and optimal target is not established; additional blinded controlled studies are needed to determine net health benefit.

Responder commonly defined as >=35% reduction in Y‑BOCS.

Multiple Sclerosis (MS) tremor: Evidence for DBS in MS tremor is limited to small nonrandomized trials and observational studies with heterogeneous targets; meta‑analytic results show improvement but exhibit high heterogeneity and publication bias; current literature does not support DBS for MS tremor as established therapy.

One controlled trial in the last decade; overall evidence insufficient.

Chronic pain: Evidence for DBS in chronic pain is limited and dated (few small RCTs and case series) with heterogeneous pain conditions and targets; systematic reviews did not adequately address publication bias and evidence is insufficient to establish efficacy.

Available RCTs small and heterogeneous (1990–2017 period).

Alcohol use disorder: A small RCT (n=12) of nucleus accumbens DBS did not find a difference in time to first alcohol use; some secondary outcomes suggested benefit but the trial was underpowered—larger trials are required before establishing efficacy.

Primary outcome negative; secondary outcomes exploratory.

Evidence summaries by indication

Evidence summaries and determinations by indication

Essential tremor: Evidence including TEC assessments and long‑term follow‑up demonstrates clinically significant tremor suppression with thalamic DBS; evidence is sufficient to determine that DBS improves net health outcome for essential tremor when trial‑level eligibility and documentation are met.

Long‑term durable benefit reported up to 5–6 years in follow‑up studies.

Parkinson disease (motor symptoms): RCTs and systematic reviews show clinically significant improvements with GPi or STN DBS in appropriately selected, levodopa‑responsive patients (for example, disease duration >=4 years or UPDRS motor >=30 off meds) with uncontrolled motor complications; evidence is sufficient to determine improvement in net health outcome.UPDRS motor >=30 off meds OR PD duration >=4 years

Meta‑analyses show no clear superiority between GPi and STN for overall motor outcomes.

Primary dystonia: Systematic reviews, RCTs, and case series show motor and disability score improvements after GPi or STN DBS; evidence is sufficient to determine benefit for primary dystonia in selected patients (age >7 years for pediatric cases).Age > 7 years

Pooled analyses demonstrate sustained improvements at 6 months and longer term in many cohorts.

Epilepsy: Systematic reviews and RCTs report seizure reductions with thalamic DBS (mean reduction ~62–69% and responder rates ~62–69% in pooled analyses), but heterogeneity, mixed randomized findings (for example, SANTE trial) and substantial adverse events leave evidence insufficient to definitively determine net health benefit across populations.

Selection should follow trial‑style criteria (drug‑resistant definition, non‑candidate for resection) and documentation of risks.

Tourette syndrome: Observational studies and small RCTs show inconsistent efficacy and high rates of serious adverse events; current evidence is insufficient to determine net health benefit and coverage should require rigorous documentation and specialist management.

Two small RCTs reported discordant results; registry data show within‑subject improvements but with notable AE rates.

Treatment‑resistant depression and other psychiatric disorders: Multiple RCTs and systematic reviews exist but many trials were negative, stopped for futility, or failed to show consistent blinded benefit; evidence is insufficient to determine net health benefit and optimal targets remain unestablished—DBS for these indications is investigational.

Adverse psychiatric events reported in several trials and open‑label series.

Other indications (Alzheimer disease, Huntington disease, anorexia nervosa, chronic pain, MS tremor, alcohol use disorder): Evidence consists largely of case series, small RCTs, or uncontrolled cohorts; evidence is inadequate to establish efficacy and DBS for these indications remains investigational pending larger randomized trials.

Specific trial examples include small RCTs with negative or inconclusive primary outcomes.

Medicare national coverage conditions for DBS (selected indications)

Covered when ALL of the following are met (Medicare coverage statement):

General device and procedural prerequisites: Device must be FDA‑approved for DBS or used under an FDA‑approved IDE protocol.

Medicare national coverage requirement.

Thalamic VIM DBS for essential tremor or tremor‑dominant Parkinson disease: Diagnosis of essential tremor (postural/kinetic hand tremors without other neurologic signs) or idiopathic tremor‑dominant Parkinson disease; marked disabling tremor (Fahn‑Tolosa‑Marin level 3 or 4) causing significant limitation despite optimal medical therapy; and willingness/ability to cooperate during awake procedures and follow‑up.Fahn‑Tolosa‑Marin level 3 or 4

Medicare criteria specify tremor severity and cooperation requirements.

STN or GPi DBS for Parkinson disease: Diagnosis of Parkinson disease with at least two cardinal features, advanced idiopathic PD as determined by Hoehn and Yahr stage or UPDRS‑III, levodopa responsiveness with defined 'on' periods, and persistent disabling Parkinson's symptoms or drug side effects (for example, dyskinesias, motor fluctuations, disabling 'off' periods) despite optimal medical therapy; willingness/ability to cooperate during awake procedures and follow‑up.

Medicare national coverage conditions for subthalamic nucleus or globus pallidus interna DBS.

Contraindications to deep brain stimulation (DBS) include patients who are not good surgical risks because of unstable medical problems or the presence of a cardiac pacemaker, patients with medical conditions that require repeated magnetic resonance imaging, and patients with dementia that may interfere with the ability to cooperate. Recent procedural guidance also flags recent botulinum toxin injections (within 6 months) as a contraindication to implantation planning. These clinical contraindications are described in the policy guidelines and should be documented when assessing a patient for DBS.

Separately, the policy notes that adaptive DBS (aDBS) has specific labeling and use limitations (FDA submission was for an optional programming feature in existing devices), which affects eligibility and device selection; refer to device labeling when proposing adaptive programming versus continuous stimulation.

Randomized trials and comparative series report procedure‑related neurologic adverse effects and device complications. Older comparative work found higher neurologic adverse effects after thalamotomy than after stimulation, but stimulation is associated with stimulation‑related effects (for example, dysarthria or disequilibrium) that are often reversible with reprogramming. Trial reports identify limitations in harms reporting and list device-related complications that require consideration in benefit–risk assessment.

Study design and conduct tables in the review emphasize incomplete or inconsistent harms reporting in many trials (for example, limited or short blinded follow-up and instances of incomplete reporting), so reviewers and authorization teams should expect reported adverse event rates to vary across studies and to request detailed device‑ and procedure‑related safety data when evaluating individual cases.

The evidence review excluded studies with duplicative or overlapping populations; this is a methodological selection criterion rather than a clinical exclusion for members. When submitting supporting literature with authorization requests, provide non‑duplicative, distinct datasets or clearly document how submitted data differ from studies already in the evidence base.

Excluding overlapping cohorts reduces double‑counting of patients and preserves the integrity of pooled estimates, but it also means that smaller series with partially overlapping samples may have been omitted from pooled summaries—document the provenance and uniqueness of registry or institutional series if relying on them for coverage justification.

Study selection favored randomized controlled trials and prospective comparative studies; single‑arm observational studies were included primarily for long‑term outcomes and adverse events. As part of that approach, trials or series with overlapping populations were excluded to avoid duplication, which can affect the set of controlled evidence available for a given indication.

For reviewers, this means that evidence summaries reflect distinct patient cohorts selected under predefined criteria; when clinical teams submit evidence or registries, ensure clear documentation that patients are not already represented in excluded or previously reviewed cohorts.

Many randomized trials in the DBS literature had short blinded follow-up periods (commonly ~3 months) and variable completeness of harms reporting. This constrains interpretation of longer‑term safety and durability of benefit, and the policy highlights incomplete reporting of key harms as a recurring study limitation.

Because longer‑term adverse events (for example, device infection, lead malpositioning, or neuropsychological effects) may emerge after blinded phases, authorization reviewers should request longitudinal follow‑up data (postoperative evaluations at serial intervals) when safety concerns are relevant to coverage decisions.

Patients who are suitable candidates for resective epilepsy surgery should be considered for resection rather than DBS. The policy and evidence review define the DBS epilepsy population as individuals with drug‑resistant epilepsy who are not candidates for resective surgery (for example, multifocal or generalized onset or other contraindications to resection), and authorization should document why resection is not appropriate.

Documentation for DBS in epilepsy requests should therefore include multidisciplinary surgical evaluation notes clarifying candidacy for resection and why less invasive or resective options are not feasible for the individual patient.

In small series of patients treated for chronic cluster headache or related facial pain targets, DBS produced variable results: some case series reported long‑term pain relief, while others documented treatment failures for atypical facial pain presentations. These mixed observational findings underscore that DBS for cluster headache and facial pain remains investigational and that outcomes can be heterogeneous.

Because surgical candidacy and expected benefit vary by pain etiology, refer to the limited case series data when assessing requests and note that atypical facial pain in small series was associated with treatment failures.

No additional explicit exclusions are stated in the excerpted evidence‑summary sections beyond the contraindications and condition‑specific noncoverage statements already described. Coverage decisions remain subject to plan terms, documented clinical justification, and the policy’s investigational lists.

This portion of the policy excerpt does not list further explicit exclusions. For indications with mixed or insufficient RCT evidence (for example Tourette syndrome), the policy expects documentation of severe, medically refractory disease and careful consideration of adverse event risk when evaluating coverage.

Small observational series of DBS for atypical facial pain reported treatment failures in the subgroup with atypical facial pain (three patients in one series), suggesting lack of benefit for those presentations in the limited data available. These findings support the policy’s conservative stance on facial‑pain indications outside well‑characterized etiologies.

DBS for major depressive disorder (MDD) is considered investigational in this policy excerpt because randomized, sham‑controlled evidence has not demonstrated consistent efficacy. Several randomized trials were terminated for futility or failed to show significant benefit in blinded phases, and psychiatric adverse events were reported more frequently in some trials; therefore DBS for MDD remains unproven outside of research settings.

Authorization requests for DBS in depression should be evaluated in the context of available trial evidence and typically will not meet medical necessity criteria unless performed in a trial or under an IDE with documented protocol‑level oversight.

The literature does not currently support DBS for multiple sclerosis (MS) tremor; available studies are small, nonrandomized, and heterogeneous in targets and outcomes. Similarly, evidence for DBS in chronic pain is limited to older, heterogeneous trials and case series with insufficient contemporary randomized data—these indications are therefore not supported by current literature for routine coverage.

Requests for DBS for MS tremor or chronic pain should include compelling, high‑quality evidence and multidisciplinary justification; absent that, these indications are treated as investigational per the policy.

Many other neurologic and psychiatric indications (for example Alzheimer disease, Huntington disease, anorexia nervosa, some chronic pain conditions, and alcohol use disorder) are supported only by small case series, observational cohorts, or very small RCTs. The policy states that the available evidence for these indications is inadequate to determine net health benefit and that larger randomized trials are required.

Consequently, DBS for these indications is considered investigational in routine clinical practice and would generally not meet medical necessity criteria outside of research protocols.

DBS is not covered for patients with non‑idiopathic Parkinson’s disease or 'Parkinson’s Plus' syndromes. Coverage is also excluded where cognitive impairment, dementia, or depression would be worsened by or interfere with benefit; in addition, active psychosis, alcohol or other substance abuse, structural lesions causing the movement disorder (for example basal ganglionic stroke or tumor), prior movement‑disorder surgery within the affected basal ganglion, or significant medical/surgical/neurologic/orthopedic comorbidities that contraindicate DBS are listed as exclusions.

These Medicare‑aligned exclusions should be considered when determining member eligibility and documenting medical necessity.

Inclusion of a billing code in the policy’s Codes section is for reference only and does not guarantee coverage. Coverage determinations depend on the member’s specific benefit plan, the clinical documentation, and the written coverage position in this medical policy.

Providers must therefore submit clinical documentation consistent with the policy’s medical‑necessity criteria in addition to the appropriate CPT/HCPCS codes to support authorization.

ICD‑10‑PCS procedure codes listed in the Codes section apply only to inpatient services. When DBS procedures are performed in an inpatient setting, appropriate ICD‑10‑PCS codes should be reported; outpatient procedures use CPT reporting as described in the Codes table.

Authorization and coding reviewers should confirm the service setting before applying ICD‑10‑PCS versus CPT guidance.

Coding and Billing Information

Coverage-related regulatory/approval statementmixed

FDA	Device must be approved by the Food and Drug Administration for deep brain stimulation or used under FDA-approved IDE protocols

DBS and neurostimulator CPT codesCPT

61850	Twist drill or burr hole(s) for implantation of neurostimulator electrodes, cortical.
61863	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site, without use of intraoperative microelectrode recording; first array.
61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array.
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to 2 or more electrode arrays.
95970	Electronic analysis of implanted neurostimulator pulse generator/transmitter without programming; brain/cranial nerve/spinal cord/peripheral nerve/sacral nerve neurostimulator.
95976	Electronic analysis of implanted neurostimulator pulse generator/transmitter with simple cranial nerve neurostimulator programming.
95977	Electronic analysis of implanted neurostimulator pulse generator/transmitter with complex cranial nerve neurostimulator programming.
95983	Electronic analysis of implanted neurostimulator pulse generator/transmitter with generator/transmitter programming by physician or other qualified health care professional (brain).

CPT codes for insertion and basic analysisCPTCovered

61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array.
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays.
95970	Electronic analysis of implanted neurostimulator pulse generator/transmitter without programming.

CPT codes for programming and extended programming timeCPTCovered

95976	Electronic analysis of implanted neurostimulator pulse generator/transmitter with simple cranial nerve neurostimulator programming.
95977	Electronic analysis of implanted neurostimulator pulse generator/transmitter with complex cranial nerve neurostimulator programming.
95983	Electronic analysis of implanted neurostimulator pulse generator/transmitter with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time.
95984	Each additional 15 minutes face-to-face time for brain neurostimulator programming (add-on).

HCPCS device supply codesHCPCSCovered

L8680	Implantable neurostimulator electrode, each.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension.

ICD-10-CM diagnostic codes referencedICD-10

G20	Parkinson's disease
G21.0-G21.9	Secondary Parkinsonism
G24.01-G24.9	Dystonia code range

ICD-10-PCS inpatient procedure codesICD-10Covered

00H00MZ	ICD-10-PCS surgical insertion codes (examples listed).
00H03MZ	ICD-10-PCS surgical insertion codes (examples listed).
00H04MZ	ICD-10-PCS surgical insertion codes (examples listed).
00H60MZ	ICD-10-PCS surgical insertion codes (examples listed).
00H63MZ	ICD-10-PCS surgical insertion codes (examples listed).
00H64MZ	ICD-10-PCS surgical insertion codes (examples listed).
00HE0MZ	ICD-10-PCS surgical insertion codes (examples listed).
00HE3MZ	ICD-10-PCS surgical insertion codes (examples listed).
00HE4MZ	ICD-10-PCS surgical insertion codes (examples listed).
00P00MZ	ICD-10-PCS codes for insertion of neurostimulator lead by body part and approach.

1–10 of 16

1/2

Unified Parkinson Disease Rating Scale (motor) — clinical threshold

UPDRS-III (motor) thresholdMinimum motor score of 30 points on the motor portion of the Unified Parkinson Disease Rating Scale when the patient has been without medication for approximately 12 hours

Alternative PD duration thresholdParkinson disease duration of at least 4 years (alternative to UPDRS ≥30 off meds)

Levodopa responsiveness requirementGood response to levodopa required for PD DBS eligibility

Medication trial duration for tremor — ≥ 3 months at maximal dosage

Medication trial duration (tremor)>= 3 months of maximal tolerated medication dose prior to considering DBS

Definition contextMedication trial described as maximal dosage with inadequate control for at least 3 months

Documentation expectationPrior authorization should document trial and inadequate control on maximal tolerated medication

Parkinson disease duration threshold — ≥ 4 years alternative to UPDRS ≥30

Parkinson disease duration threshold>= 4 years of Parkinson disease (alternative to meeting UPDRS motor score ≥30 off meds)

Use as alternative criterionCan be used in lieu of UPDRS-III ≥30 when documenting eligibility for STN or GPi DBS

Requirement linkageAlso requires good levodopa response and motor complications not controlled by pharmacologic therapy

Responder definition (epilepsy) — ≥50% seizure reduction

Epilepsy responder definitionResponder defined as ≥50% reduction in seizure frequency

Outcome useResponder rate used as primary efficacy metric in SANTE and in meta-analyses of thalamic DBS

Documentation expectedBaseline seizure frequency and diaries recommended to assess responder status

QOLIE-31 minimally important change — 5 points

QOLIE-31 minimally important change5-point change on the QOLIE-31 considered the minimally important change

Context of useUsed to assess quality-of-life impact in treatment-resistant epilepsy trials

Trial reportingQOLIE-31 scores reported in SANTE and other epilepsy outcome assessments

Tremor severity (Fahn-Tolosa-Marin) — Level 3 or 4 disabling tremor

Fahn‑Tolosa‑Marin severity requirementMarked disabling tremor defined as level 3 or 4 on the Fahn‑Tolosa‑Marin Clinical Tremor Rating Scale in the extremity intended for treatment

Functional impactLevel 3–4 tremor must cause significant limitation in daily activities despite optimal medical therapy

Medicare alignmentThis severity threshold is specified in Medicare national coverage conditions referenced by the policy

Programming time increment — 95983 first 15 min; 95984 each additional 15 min

Initial programming time (CPT 95983)95983 — electronic analysis with brain neurostimulator programming, first 15 minutes face-to-face time

Additional programming time (CPT 95984)95984 — each additional 15 minutes face-to-face time (add-on to 95983)

Use guidanceReport 95983 for initial 15 minutes of programming and append 95984 for each additional 15-minute increment

Neurostimulator programming/analysis codes — list of CPT codes for programming/analysis

CPT codes — neurostimulator programming/analysis95970, 95976, 95977, 95983, 95984 describe electronic analysis and programming of implanted neurostimulator pulse generators/transmitters

Insertion/generator CPTs (reference)61885, 61886 for insertion or replacement of cranial neurostimulator pulse generator; 61850/61863 for electrode insertion procedures (listed in Codes table)

HCPCS device supply codesL8680, L8685, L8686, L8687, L8688 describe implantable neurostimulator electrodes and pulse generators

ICD-10-PCS inpatient procedure codesExamples include 00H00MZ, 00H03MZ, 00P00MZ series for inpatient neurostimulator insertion

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior authorization required; use Codes table

Prior authorization is required per payer coding and authorization processes; refer to the policy Codes table for the specific CPT, HCPCS and ICD-10-PCS codes to report when submitting an authorization request.

See Codes table referenced in the policy for CPT/HCPCS code sets to report.
Inpatient procedures should use ICD-10-PCS codes when applicable.

Documentation Required

Document target nucleus and laterality

Authorization requests must specify the anatomic DBS target (e.g., thalamus/VIM, subthalamic nucleus, or globus pallidus interna) and whether stimulation is intended unilateral or bilateral.

Document the specific nucleus targeted.
Document laterality (unilateral vs bilateral) for the intended treatment.

Prior Authorization

Document device model and adaptive programming use

If adaptive (closed‑loop) DBS programming is requested, prior authorization should state the device model and that adaptive programming (aDBS) is being requested instead of continuous DBS.

State the neurostimulator model (Medtronic Percept™ PC or equivalent) and the aDBS mode requested (single- or dual-threshold).
Indicate that adaptive programming is requested rather than continuous DBS.

Prior Authorization

Confirm target, indication, and prior therapies

Prior authorization must confirm the planned target (GPi or STN), the clinical indication (e.g., Parkinson disease or primary dystonia), and document prior therapies tried (pharmacologic therapy, botulinum toxin, or neuroablative procedures for dystonia where applicable).

Confirm GPi or STN as the intended target when applicable.
Provide records of prior conservative therapies attempted and outcomes.

Prior Authorization

Document trial‑equivalent eligibility (diagnosis, duration, prior therapy, disability)

Prior authorization should include trial-equivalent eligibility documentation: diagnosis, disease duration, prior optimal pharmacologic treatment, and demonstration of marked disability comparable to trial entry criteria.

Provide disease duration and documentation of prior optimized medical therapy.
Include objective measures of disability/severity used in trials (e.g., BFMDRS, TWSTRS, UPDRS where applicable).

Prior Authorization

Document drug‑resistant epilepsy and prior antiseizure trials

For DBS for drug‑resistant epilepsy, prior authorization must document failure of adequate trials of antiseizure medications (definition: failure of 2 appropriately chosen and tolerated antiepileptic drugs) and that the patient is not a candidate for resective surgery.

Specify number and names of antiseizure drugs tried and reasons for failure.
Provide baseline seizure frequency and diary data.

Prior Authorization

Prior authorization likely required for epilepsy DBS

Prior authorization is likely required for DBS for drug‑refractory epilepsy given mixed randomized evidence and safety concerns; include detailed prior therapy history and trial-aligned selection criteria in the request.

Include number of failed medications (e.g., ≥3 for some trials) and prior non‑surgical therapies considered (VNS, ketogenic diet).
Provide documentation addressing safety considerations (device‑related SAEs) from prior records.

Prior Authorization

Verify medically refractory disease and prior conservative therapies

Prior authorization should verify severe, medically refractory disease and that prior conservative/medical therapies have been tried and failed before approving DBS.

Provide evidence of failed conservative/medical management and rationale for DBS.
Provide center expertise and follow-up plan when requested.

Prior Authorization

Confirm standard therapies attempted for cluster headache

For DBS requests in cluster headache and related conditions, prior authorization must confirm that guideline-recommended acute and prophylactic therapies (e.g., oxygen, triptans, verapamil, steroids, botulinum toxin) were attempted and failed.

Document trials of acute therapies (oxygen, triptans) and prophylactic agents (verapamil, steroids).
Explain why DBS is being considered despite high placebo response in cluster headache trials.

Prior Authorization

Require prior authorization with trial‑level rationale and severity measures

Prior authorization is recommended for DBS requests because randomized trials for many indications have inconsistent benefit and significant psychiatric adverse events; submissions should include prior treatment history and objective severity measures.

Provide objective severity scales and prior treatment documentation.
Cite trial evidence or rationale supporting the proposed target/indication.

Prior Authorization

Require trial‑level evidence and prior therapy documentation

Prior authorization should require submission of methodologically credible evidence (preference for RCTs or comparative prospective trials) and documentation of prior standard therapies tried when relevant to the indication.

Attach relevant RCTs or high-quality comparative studies when available.
Document prior standard-of-care therapies and responses.

Prior Authorization

Verify guideline‑supported criteria, indication and target

Prior authorization must verify that the patient meets guideline-supported criteria for the indication and target (for example, levodopa‑responsive PD with uncontrolled motor symptoms for STN/GPi DBS) and include specialist evaluations.

Confirm levodopa responsiveness and motor complication status for PD.
Include specialist (neurology/neurosurgery) evaluation notes.

Prior Authorization

Verify device approval/IDE use and documented eligibility criteria

Prior authorization should verify use of an FDA‑approved device or inclusion in an FDA‑approved IDE protocol and document that the patient meets the documented diagnostic and severity criteria (e.g., tremor severity scales, UPDRS thresholds).

Confirm device FDA approval status or IDE protocol identifier.
Provide severity measurements (Fahn‑Tolosa‑Marin level, UPDRS scores) per Medicare-style conditions when applicable.

Billing Rule

Codes listed for reference; coverage per member plan

Codes listed in the policy (CPT/HCPCS/ICD-10-PCS) are provided for reference; inclusion of these codes does not guarantee member coverage — coverage is subject to member‑specific benefit plan terms and the medical policy.

Use the policy code lists as reference only; confirm member plan coverage rules.
Inpatient procedure coding requires ICD-10-PCS codes when applicable.

Billing Rule

Report specified CPT/HCPCS codes; use ICD‑10‑PCS for inpatient

Providers must report the specific CPT and HCPCS codes listed for neurostimulator insertion/replacement, electronic analysis and programming, and device supplies; inpatient services should be reported with ICD-10-PCS codes.

Report CPT codes for insertion (e.g., 61885, 61886) and programming/analysis (95970, 95976, 95977, 95983, 95984) as applicable.
Use HCPCS device supply codes (L8680-L8688) for implanted components.
Use ICD-10-PCS procedure codes for inpatient implantations.

Step Therapy

Document failed maximal medical therapy and levodopa responsivity

When requesting DBS for Parkinson disease or disabling tremor, providers must show inadequate control with maximal tolerated medication (for tremor: at least 3 months) and, for PD, demonstrate a good levodopa response when applicable.

For tremor: document trial of maximal tolerated medication for ≥3 months.
For PD: document levodopa responsivity and motor complications not controlled pharmacologically.

Step Therapy

Document prior conservative therapies and rationale

Conservative therapies (pharmacologic therapy, consideration of neuroablative procedures) are relevant comparators and should be documented as attempted or contraindicated prior to DBS.

List prior pharmacologic and procedural alternatives tried and reasons for discontinuation or failure.
If neuroablative procedures were avoided, document rationale.

Step Therapy

Show prior conservative management attempted

Document prior conservative management (pharmacologic therapy, physical/speech therapy) attempts and outcomes, as these are relevant comparators before consideration of DBS.

Provide records of trials of physical/speech therapy when relevant to functional impairment.
Include medication lists and response histories.

Step Therapy

Require documentation of failed conservative therapies for dystonia

For primary dystonia, prior authorization/authorization review should document trials of conservative therapies (oral/injectable medications, botulinum toxin) and consideration of neuroablative procedures before DBS.

Document botulinum toxin use and response, oral medication trials, and reason for moving to DBS.
Include duration of disease and prior therapy adequacy per trial criteria.

Step Therapy

Document failure of optimal pharmacologic therapy

Ensure records show unsatisfactory response to optimal pharmacologic therapy (and sham‑controlled trial context where applicable) before DBS is approved.

Provide evidence that pharmacologic therapy was optimized and ineffective.
When trials used sham comparators, align documentation to trial‑equivalent features where feasible.

Step Therapy

Require failure of medications and non‑surgical options before epilepsy DBS

Step‑therapy expectations require that patients have tried and failed pharmacologic therapy and other appropriate non‑surgical options (e.g., vagus nerve stimulation) before DBS is considered for drug‑resistant epilepsy.

Document prior antiseizure medication trials (names, doses, durations) and responses.
Document trials or consideration of VNS or ketogenic diet where applicable.

Step Therapy

DBS for Tourette: document failed medical and behavioral therapy

For Tourette syndrome, DBS is considered a later‑line therapy after optimal medical management and cognitive‑behavioral therapy have failed for disabling tics; prior authorization should document these prior treatments.

Provide documentation of trials of medications, behavioral therapy (habit reversal), and outcomes.
Document tic severity (baseline YGTSS) and functional impairment.

Step Therapy

Require failure of guideline‑recommended treatments for cluster headache

For cluster headache, prior authorization should document trials of guideline‑recommended acute and prophylactic therapies (oxygen, triptans, verapamil, steroids, botulinum toxin) before DBS is considered.

List acute and prophylactic therapies tried, durations, and responses.
Explain limitations or contraindications to standard therapies if applicable.

Step Therapy

Document prerequisite acute and preventive therapy trials

Providers should document trials of guideline‑recommended acute and prophylactic therapies (examples: oxygen, triptans, verapamil, steroids) and other prerequisite treatments before considering DBS.

Provide dates, doses, and outcomes of acute and prophylactic therapy trials.
Document any contraindications to standard treatments.

Step Therapy

Require failure of conventional therapies before DBS

DBS is considered only after conventional therapies (appropriate pharmacologic therapy, cognitive‑behavioral therapy, and other surgical interventions) have been tried and failed; prior authorization should include this evidence.

Provide a timeline of prior therapies and objective measures of nonresponse.
If conventional therapies were not used, document clinical rationale.

Step Therapy

Document conservative therapy attempts (pharmacologic/behavioral) first

Conservative therapies (appropriate pharmacologic therapy, behavioral therapy, psychotherapy) should be tried and documented prior to considering DBS; sham‑controlled trials remain the comparator in RCTs.

Document behavioral and pharmacologic therapy trials with dates and outcomes.
When applicable, indicate reasons why sham‑controlled trial features are not relevant to the individual case.

Step Therapy

Align step‑therapy documentation with guideline expectations

Guideline and evidence inputs emphasize DBS for medically refractory conditions after failure of medical therapy; prior authorization and documentation should align with those expectations.

Align prior therapy documentation with society or Medicare criteria where available.
Provide objective severity and disability measures used by guidelines.

Documentation Required

Document failure of optimal medical therapy (specific examples required)

Providers must document failure of optimal medical therapy prior to DBS consideration (examples: two or more appropriately dosed antiseizure medications for epilepsy; maximal tolerated medication for tremor; levodopa responsiveness for PD).

List medications tried, doses, durations, and documented inadequate response or intolerance.
Include objective severity thresholds where applicable (e.g., UPDRS, Fahn‑Tolosa‑Marin levels).

Note

Documentation Required

Document disabling, medically unresponsive tremor (≥3 months trial)

Document disabling tremor as medically unresponsive by showing a trial of maximal tolerated medication for at least 3 months and evidence of functional limitation interfering with daily activities.

Provide duration and doses of medication trials (≥3 months at maximal tolerated dose).
Include functional impact documentation (ADL impairment, tremor rating scores).

Documentation Required

Provide baseline and longitudinal postoperative outcome documentation

For outcome monitoring and medical‑necessity support, include baseline and serial postoperative evaluations (examples: 1, 3, 6, 12, 24, 36 months, up to 5 years) documenting symptom severity and adverse events.

Provide baseline measures and scheduled follow-up assessments used to monitor efficacy and harms.
Include device/procedure adverse events and programming adjustments in follow-up documentation.

Documentation Required

Include trial‑eligibility details (duration, levodopa response) for PD

Trial‑eligibility examples to include in authorization: disease duration, levodopa responsiveness (≥50% motor improvement), and Parkinson disease details that mirror trial inclusion criteria.

Report levodopa response magnitude and UPDRS or Hoehn & Yahr staging where available.
Document disease duration and prior medication adjustments.

Documentation Required

Provide PD diary and trial endpoints (On time without troublesome dyskinesia)

For PD trial‑style endpoints, provide Parkinson's Disease Home Diary data (e.g., 'On' time without troublesome dyskinesia) and baseline cDBS/aDBS evaluation phase diaries and adverse event reporting when relevant.

Attach patient diary data used to assess 'On' time and dyskinesia burden.
Include programming parameters for baseline cDBS and aDBS evaluation phases if applicable.

Documentation Required

Provide trial‑aligned diagnostic and severity documentation

Documentation should demonstrate diagnostic criteria, disease duration, prior treatment failures, and severity measures used in credible trials to support medical necessity.

Show alignment between patient characteristics and trial eligibility where possible.
Include validated rating scale scores used in the literature (BFMDRS, TWSTRS, YGTSS, UPDRS).

Documentation Required

Confirm failure of adequate antiseizure medication trials and provide seizure diary

Required documentation for epilepsy DBS: confirm failure of adequate trials of antiseizure medications (definition: failure of 2 appropriately chosen and tolerated drugs; some trials required ≥3) and include seizure diaries and baseline seizure frequency.

List antiseizure medications tried with doses and durations and reasons for failure.
Include seizure diary entries and baseline frequency to support responder assessment.

Documentation Required

Provide seizure baseline, diary data, procedural details and follow‑up

Suggested supporting documentation to establish medical necessity for epilepsy DBS includes evidence of prior drug‑refractory status, baseline seizure frequency/diary data, procedural details, target nucleus, device‑related AE history, and follow-up seizure frequency.

Provide SANTE‑style follow‑up data when available (long‑term seizure frequency and responder status).
Include device/procedure complications and management.

Documentation Required

Provide severity, prior‑treatment history, baseline YGTSS and target rationale

Suggested clinical documentation for indications such as Tourette syndrome should include severity and duration of disease, prior treatments tried and failed, baseline YGTSS, and rationale for chosen target.

Include baseline YGTSS and functional impact.
Explain target selection and prior multidisciplinary evaluations.

Documentation Required

Provide baseline severity scales and prior treatment history for headache/depression

Required clinical documentation for headache or depression indications should include baseline severity and frequency using validated scales (e.g., weekly attack frequency, VAS for headache; Hamilton or Montgomery–Asberg for depression), prior treatments tried and responses, and assessment of safety risks.

Attach validated scale scores and prior treatment timelines.
Document safety risk assessment (stroke, infection, cognition, mood).

Documentation Required

Provide trial‑style documentation for long‑standing, treatment‑resistant illness

Clinical trial–style documentation expectations include evidence of long‑standing, treatment‑resistant illness (examples: depression ≥12 months, failure of multiple medication trials) and reporting of both response/remission and adverse events.

Provide duration of illness and complete treatment history.
Report both efficacy outcomes and adverse event monitoring plans.

Prior Authorization

Submit comparative trial data and prior treatment history when available

Prior authorization and documentation should include comparative controlled prospective trial data when available and a record of prior treatments attempted (pharmacologic, behavioral, psychotherapy), target rationale, and relevant efficacy/safety measures.

Attach relevant controlled trial citations and how the patient aligns with trial populations.
Provide functional status, quality of life, and key safety event documentation.

Documentation Required

Include diagnosis, prior treatment failures, target rationale and evidence basis

Suggested supporting documentation for authorization includes diagnosis, prior treatments tried and failed (e.g., medically refractory tremor, levodopa‑responsive PD uncontrolled on meds), target brain region, and evidence of expected benefit based on RCTs or systematic reviews.

Cite RCTs or systematic reviews that support the proposed indication and target.
Include specialist letters summarizing expected benefit and follow‑up plans.

Documentation Required

Meet Medicare‑style device and documentation requirements when applicable

Medicare-style documentation requirements should be verified for applicable members: device FDA approval or IDE protocol use, documented diagnosis and disease severity (e.g., tremor rating scales or UPDRS/Hoehn and Yahr for PD), failure of optimal medical therapy, and willingness/ability to cooperate with awake procedures and follow‑up.

Confirm device approval status and include severity scores per Medicare conditions.
Document patient ability and willingness to participate in awake operations and follow‑up.

Billing Rule

Align coding and documentation with member benefit plan

Coding guidance provided in the policy is for reference; ensure that documentation and code reporting align with the member‑specific benefit plan and the written coverage position in this medical policy.

Confirm member plan terms before submitting claims.
Use the policy's code lists only as guidance and include supporting documentation with authorizations.

Billing Rule

Report specific CPT/HCPCS codes for insertion, programming and supplies

Use accurate CPT and HCPCS codes for insertion/replacement of cranial neurostimulator pulse generator (e.g., 61885, 61886), electronic analysis and programming (95970, 95976, 95977, 95983, 95984), and device supplies (L8680–L8688) as listed in the policy when reporting services.

Report first 15 minutes of programming with 95983 and additional 15‑minute increments with 95984.
Include appropriate L‑series HCPCS device supply codes for implanted generators and electrodes.

Denial Risk

Risk of denial for investigational indications

Denial risk exists if DBS is requested for indications the policy labels investigational (examples include adaptive DBS for PD, DBS for cluster headache, epilepsy, Tourette syndrome, depression, OCD, Alzheimer disease, MS tremor, chronic pain, and tardive syndromes).

Check the policy’s investigational/not‑covered list before submitting an authorization.
Provide clinical justification and trial evidence if requesting coverage for an investigational indication.

Note

Avoid duplicative/overlapping study evidence submissions

Studies with duplicative or overlapping populations were excluded from the evidence selection; provide non‑duplicative supporting data and clearly identify patient‑level differences when submitting trial evidence.

Indicate whether submitted publications include overlapping cohorts and clarify differences.
Prefer methodologically credible, non‑duplicative evidence for justification.

Denial Risk

Denial risk if study‑level eligibility or prior therapy documentation lacking

Insufficient evidence or failure to meet study‑level criteria (e.g., inadequate prior therapy trials or short blinded assessment alignment) could lead to denial; ensure authorization documentation addresses trial selection and eligibility criteria.

Document how the patient meets or differs from trial inclusion criteria.
Provide full prior therapy history to avoid denials for inadequate characterization of refractoriness.

Denial Risk

Denial risk from limited trial evidence or missing prior‑therapy proof

Trials reported limited sample sizes, short blinded periods, and underpowered analyses; authorization requests lacking sufficient evidence of benefit or lacking prior standard‑of‑care therapy documentation may be denied.

Address sample‑size and blinded‑period differences between the patient and cited trials.
Provide robust objective measures and prior therapy documentation to mitigate denial risk.

Denial Risk

Additional review or denial possible for epilepsy DBS due to evidence uncertainty

Evidence uncertainty for DBS in drug‑refractory epilepsy (mixed RCT results and notable serious adverse events) may prompt denial or additional review; include detailed justification and safety/risk mitigation plans when requesting approval.

Provide rationale for DBS over alternative options (VNS, resection) and address safety mitigation.
Include long‑term follow‑up plans and monitoring strategies.

Denial Risk

Denial risk when SAEs are high or RCT evidence equivocal

High rates of serious adverse events reported in some RCTs and mixed randomized evidence for certain indications (e.g., psychiatric disorders) may trigger denial or require careful benefit‑risk documentation.

Describe anticipated adverse event risks and plans for monitoring and management.
Provide specialty‑center capability to manage device/procedure complications.

Denial Risk

Denial risk if no benefit over sham or no documentation of standard therapies

Lack of evidence of benefit over sham or failure to document prior standard therapies (e.g., medical therapy, oxygen, triptans) may lead to denial; submissions must document prior standard‑of‑care attempts and why DBS is indicated.

Provide comparisons to prior standard therapies and justify DBS as next‑step therapy.
If sham‑controlled RCTs were negative, explain patient‑level differences or rationale for DBS use.

Denial Risk

High denial risk for DBS in treatment‑resistant depression without research context

Because RCTs for major depressive disorder have been inconclusive or terminated for futility, requests for DBS in MDD outside research settings may be denied; include trial‑level justification and comprehensive prior treatment history if requested.

Document prior trials of medications, psychotherapy, and ECT and their outcomes.
Provide rationale referencing available RCTs and why DBS is being considered.

Denial Risk

Denial risk for indications with insufficient evidence

Evidence limitations across multiple indications (small samples, heterogeneity, risk of bias) may lead to noncoverage or denial when DBS is proposed for indications lacking supportive evidence; show strong justification and prior therapy failure documentation to reduce this risk.

Provide comprehensive prior‑therapy histories and objective severity measures.
If evidence is limited, document why the individual patient may still benefit.

Denial Risk

Authorization impacted by high AE rates or inconsistent efficacy

High adverse event rates and inconsistent efficacy reported in some RCTs (for example, epilepsy trials) may affect authorization decisions; include explicit monitoring and management plans in the authorization package.

Describe perioperative and long‑term adverse event surveillance plans.
Provide center experience and reoperation/complication management resources.

Denial Risk

Exclude requests with listed clinical contraindications (Parkinson's Plus, dementia, psychosis, structural lesions)

DBS is not covered for non‑idiopathic Parkinson's disease or 'Parkinson's Plus' syndromes, for patients with cognitive impairment/dementia or active psychosis/substance abuse, or for structural lesion etiologies; authorization requests for such patients should be declined.

Verify absence of exclusionary conditions (Parkinson's Plus, dementia, psychosis, substance abuse, structural lesions).
If exclusions are present, do not approve DBS for those cases.

Note

Code inclusion does not guarantee coverage; verify member plan

Inclusion of a code in the policy does not guarantee coverage; all benefit determinations are subject to the member‑specific benefit plan and the written coverage position set forth in this medical policy.

Confirm member coverage details prior to scheduling or performing procedures.
Use policy codes as guidance but obtain authorization per plan requirements.

Billing Rule

Use ICD‑10‑PCS for inpatient DBS procedures; CPT/HCPCS for outpatient

ICD-10-PCS procedure codes must be used for inpatient DBS services; outpatient reporting should use CPT/HCPCS codes as listed in the policy.

Use ICD-10-PCS codes for inpatient insertions and relevant inpatient procedure reporting.
Use CPT/HCPCS codes for outpatient DBS insertions, programming and device supplies.

Note

Background and Definitions

Deep brain stimulation (DBS) uses stereotactic placement of intracranial electrodes connected to an implanted programmable neurostimulator to deliver electrical stimulation to targeted brain regions (for example thalamus, subthalamic nucleus, globus pallidus interna).

DBS may be performed unilaterally or bilaterally depending on symptom laterality and is programmable so that stimulation parameters can be adjusted noninvasively to balance symptom control against stimulation‑related adverse effects such as dysarthria, disequilibrium, or involuntary movements. Adaptive DBS (aDBS) is a closed‑loop approach that adjusts stimulation based on recorded brain signals and has regulatory/labeling limitations as an optional programming feature.

Definition — Disabling, medically unresponsive tremor (clinical threshold)

DefinitionTremor causing significant limitation in daily activities and inadequately controlled by maximal dosage of medication for at least 3 months before implant

Key elementsRequires demonstration of functional limitation and documented trial of maximal tolerated medications for ≥3 months

RelevanceUsed to determine medical necessity for thalamic DBS for essential tremor or Parkinson disease tremor

Definition — Adaptive DBS (aDBS) concise definition

Concise definitionAdaptive deep brain stimulation (aDBS) is a closed-loop DBS system that incorporates feedback from brain signals (local field potentials) to dynamically adjust stimulation parameters

Intended benefitDesigned to personalize therapy and potentially reduce stimulation duration and energy consumption while addressing motor symptoms and dyskinesia

Regulatory noteMedtronic submitted aDBS as an optional programming feature for existing devices; labeling limits use with more than one implanted neurostimulator

Definition — Deep brain stimulation (DBS)

DBS definitionStereotactic surgical implantation of intracranial electrodes connected to an implanted programmable neurostimulator to deliver continuous or adjustable electrical stimulation to specific brain targets (thalamus, subthalamic nucleus, globus pallidus interna)

Procedure elementsElectrodes may be tested with temporary stimulation then connected to a permanent subcutaneous pulse generator; programming is noninvasive and adjusted postoperatively

UseUsed unilaterally or bilaterally depending on symptom laterality and target indication

Definition — Adaptive deep brain stimulation (policy note)

Policy note definitionAdaptive deep brain stimulation is described as an optional programming feature for Parkinson disease available in existing Medtronic DBS systems that adapts stimulation parameters rather than delivering continuous stimulation

LimitationsNot studied in bilaterally implanted neurostimulators per FDA submission; labeling instructs not to use aDBS with more than one implanted neurostimulator

Evidence stanceOne RCT (ADAPT-PD) evaluated aDBS; policy notes insufficient evidence to determine net health benefit

Definition — Continuous deep brain stimulation (comparator)

Continuous DBS (comparator)Traditional DBS programming delivering constant stimulation used as the comparator for evaluations of adaptive DBS

Programming contextPatients typically receive continuous DBS baseline prior to adaptive programming phases in trials

Clinical balanceContinuous stimulation requires balancing symptom control against stimulation-related adverse effects (e.g., dysarthria)

Definition — Adaptive deep brain stimulation (technical detail)

Technical detail (aDBS)aDBS adjusts stimulation amplitude in response to real-time fluctuations in local field potentials (LFPs), tested in single- and dual-threshold modes in ADAPT-PD

Trial modesSingle-threshold and dual-threshold algorithms were evaluated, with different success rates reported in the pivotal trial

Programming targetsApplied to STN or GPi leads with ring or directional configurations in trial cohorts

Definition — Primary dystonia

Primary dystonia — definitionA movement disorder in which dystonia is the only symptom and is unassociated with other pathology; may be focal, multifocal, or generalized

Clinical featuresCharacterized by sustained or intermittent muscle contractions causing abnormal movements or postures

Pediatric noteTrials included pediatric patients; policy references age threshold for coverage (>7 years)

Definition — Primary (isolated) dystonia

Primary (isolated) dystonia definitionDystonia characterized by sustained or intermittent muscle contractions causing abnormal movements or postures; trials often targeted GPi DBS and included segmental or generalized forms

Evidence noteSystematic reviews and RCTs (Kupsch, Volkmann) support efficacy of pallidal DBS in primary dystonia

Age relevancePolicy cites studies including patients >7 years; coverage criteria reference age >7 years for medically necessary DBS

Definition — Tardive dystonia/dyskinesia

Tardive dystonia/dyskinesia definitionMedication-induced movement disorders, often from dopamine receptor–blocking agents, with persistent involuntary movements; trials evaluated pallidal DBS in patients with marked disability and disease duration ≥18 months

Trial evidenceOne RCT (Gruber et al 2018) randomized 25 patients but was underpowered and did not show significant difference at 3 months

Safety noteAdverse events occurred in 10 of 25 patients; 3 serious events reported in the trial

Definition — Drug‑resistant epilepsy

Drug‑resistant epilepsy definitionFailure of adequate trials of 2 tolerated, appropriately chosen and administered antiepileptic drugs (monotherapy or combination) to achieve seizure freedom

Candidate selectionIncludes patients not candidates for resective surgery (multifocal onset, generalized onset, or significant comorbidity)

Guideline referenceDefinition aligned with ILAE consensus cited in policy

Definition — Responder rate (epilepsy)

Responder rate (epilepsy)Proportion of patients achieving ≥50% reduction in seizure frequency used as responder rate in trials and meta-analyses

Use in SANTE and meta-analysesResponder rates for anterior nucleus and centromedian nucleus reported ~61–69% in pooled analyses

Outcome implicationsResponder rate is a key efficacy outcome but seizure freedom rates were low in pooled data

Definition — Responder (general epilepsy trials)

General responder definition (epilepsy trials)Responder defined as participant achieving ≥50% reduction in seizure frequency

Trial applicationUsed as primary or secondary endpoint in SANTE and other epilepsy studies

DocumentationBaseline seizure diaries and follow-up frequency required to assess responder status

Definition — YGTSS (Tourette)

YGTSS (Tourette) overviewYale Global Tic Severity Scale (YGTSS) is a 0–100 scale measuring tic severity with motor and vocal subscales; lower scores indicate less severe symptoms

Outcome usageUsed to measure tic severity and response in Tourette syndrome DBS studies

Score interpretationTotal score combines motor and vocal tic severity and impairment components

Definition — Yale Global Tic Severity Scale (YGTSS) detailed

YGTSS detailed descriptionYale Global Tic Severity Scale is a clinician-rated 0–100 scale with motor and vocal tic subscales; used to assess baseline and follow-up tic severity in DBS studies

Score range and meaningLower scores indicate less severe symptoms; used to calculate percent reduction and responder rates in pooled analyses

Trial reportingPooled analyses report median reductions and responder proportions using YGTSS

Definition — Cluster headache (chronic vs episodic)

Cluster headache definition (chronic vs episodic)Primary trigeminal autonomic cephalalgia with severe unilateral orbital/supraorbital/temporal pain lasting 15–180 minutes; episodic defined by cluster periods separated by pain-free remission ≥3 months, chronic defined as attacks ≥1 year without remission or with remission <3 months

Typical age and sex distributionAge at onset generally 20–40 years; men affected ~3 times more often than women

Diagnostic requirementsAt least 5 attacks required plus ipsilateral autonomic features or restlessness/agitation

Definition — Response (headache/pain/depression trial definitions)

Response definitions (headache/pain/depression)Headache/pain response commonly defined as >50% (or 75%/100%) decrease in headache days per month; depression response commonly defined as ≥50% reduction on validated depression rating scales

ApplicationUsed as key efficacy thresholds in trials for cluster headache, pain, and depression-related DBS studies

Remission vs responseRemission defined by achieving prespecified low absolute score (e.g., HAM-D threshold) while response is percent improvement

Definition — YBOCS (OCD)

YBOCS (OCD)Yale‑Brown Obsessive Compulsive Scale is a 10-item clinician-rated scale for OCD severity; a score ≥24 indicates severe illness; response often defined as ≥35% reduction

Use in trialsY‑BOCS used as primary outcome in DBS trials for OCD to define response and remission

Responder thresholdResponder commonly defined as ≥35% reduction in Y‑BOCS

Definition — Responder (depression trials)

Responder (depression trials)Frequently defined as ≥50% improvement from baseline on depression rating scales (e.g., Montgomery‑Åsberg or Hamilton Depression Rating Scale)

RemissionOften defined by achieving a prespecified low score on the chosen depression scale (e.g., HAM‑D ≤7)

Trial nuancesRandomized phases sometimes follow lengthy open‑label optimization periods, which can bias randomized comparisons

Definition — DBS targets (anatomic targets referenced)

DBS targets — overviewAnatomic targets referenced include affective/limbic structures (ventral striatum/ventral capsule, anterior limb of internal capsule, subgenual cingulate), memory-related structures (fornix, nucleus basalis), and motor targets (various thalamic nuclei, STN, GPi)

Parkinson disease targetsBilateral STN or GPi stimulation are primary motor targets; STN favored for medication reduction, GPi favored to lessen cognitive decline or treat on‑medication dyskinesias

Target selection importanceTarget selection should be documented and justified for the indication and patient characteristics

Definition — Responder (OCD)

Responder (OCD)Defined in reviewed studies as ≥35% reduction in Yale‑Brown Obsessive‑Compulsive Scale (Y‑BOCS) score

Outcome reportingResponder and mean Y‑BOCS change reported in systematic reviews and pooled analyses

Evidence certaintyPooled response rates reported but heterogeneity and small sample sizes limit certainty

Definition — Adaptive deep brain stimulation (aDBS) — alternate reference

aDBS alternate referenceaDBS adjusts stimulation parameters in response to physiologic signals; ADAPT‑PD RCT reported feasibility and efficacy metrics (e.g., 78.9% ST‑aDBS, 91.0% DT‑aDBS success rates) but notable adverse event rates

Regulatory contextMedtronic submitted aDBS as an optional programming feature for existing devices; labeling limits bilateral device use

Evidence stancePolicy concluded evidence is insufficient to determine net health benefit for aDBS

Definition — Medically refractory OCD

Medically refractory OCDOCD that has failed appropriate prior treatments (pharmacologic and behavioral therapies); guideline bodies note level I evidence for bilateral STN DBS and level II for other bilateral targets

Candidate selectionPatients typically required to have severe, treatment‑refractory illness and documented prior treatment failures

Guideline citationASSFN/CNS guidance summarized in policy supports use in select refractory cases with specified targets

Definition — Medication-refractory epilepsy (ASSFN cited)

Medication‑refractory epilepsy (ASSFN cited)Confirmed focal‑onset epilepsy with failure of seizure control after two or more appropriately dosed antiseizure meds, seizures not amenable to resection or with failed resection

ASSFN positionASSFN 2022 position statement lists criteria for DBS candidacy including prior medication failures and non‑resectability

DocumentationPrior authorization should document drug‑resistant status and prior therapies tried

Definition — DBS targets for Parkinson disease (STN, GPi guidance)

PD DBS targets guidanceBilateral STN or GPi stimulation for Parkinson disease; STN favored for medication reduction, GPi favored for reducing cognitive or psychiatric risk or treating on‑medication dyskinesias

Equivalence noteGuidelines report similar efficacy for motor symptom improvement between STN and GPi

Selection factorsTarget choice should consider medication reduction goals, cognitive risks, and dyskinesia management

Definition — Drug-resistant epilepsy per ILAE consensus

Drug‑resistant epilepsy (ILAE) referencePolicy references ILAE consensus (Kwan et al., Epilepsia 2010) definition of drug‑resistant epilepsy consistent with failure of ≥2 appropriately chosen antiseizure drugs

Clinical implicationUsed to determine eligibility for DBS when resective surgery is not appropriate

Documentation expectationBaseline seizure frequency and trials of antiseizure meds should be documented

Policy Changes and Revision History

2026-04-30adoption_effectiveLatest

Blue Cross of Idaho adopted policy updates effective 04/30/2026; literature review through April 9, 2026; adaptive deep brain stimulation in Parkinson disease was added to the policy evidence review and investigational policy statement.

2025-04-24evidence_update

Policy updated with literature review through March 4, 2025 and references added; evidence review and investigational policy statement for adaptive deep brain stimulation in Parkinson disease were added.

2024-04-25evidence_update

Policy updated with literature review through February 22, 2024 and references added.

2025-04-24material_change

Adaptive deep brain stimulation in Parkinson disease was added to the policy evidence review and investigational policy statement (material change).

2026-04-30confirmationLatest

Adaptive deep brain stimulation remained addressed in the evidence review and investigational policy statement when the policy was updated with literature through April 9, 2026 and adopted effective 04/30/2026.